MSNZ Submission on the Online Casino Gambling Bill
Multiple Sclerosis NZ has made a submission on the proposed new Online Casino Gambling Bill which puts the sustainability of many MS community services and organisations at risk. We have grave concerns that granting 15 licenses to online gambling operators, including overseas companies, will simply take profits offshore. For over 50 years, profits from Class […]
Our Submission to Disability Support Services Consultation
Following our two open platform sessions on 12th March where we gathered your comments, insights and feedback into the review of Disability Support Services (DSS), we are pleased to share with you our submission and recommendations. During our sessions, we heard your comments: “It is extremely dis-empowering. Unless you know your rights and entitlements.” “It […]
Mavenclad® Cladribine – Have your Say by Friday 22nd September 2023
Mavenclad® Cladribine – Have your Say MSNZ is currently preparing a submission to Pharmac to urge them to again consider funding Mavenclad (Cladribine) for Relapsing Remitting MS. Our submission is due this Friday 22nd September. Real world and clinical trial data shows the treatment benefits for those with Relapsing Remitting MS. It is also available […]
Accessibility for New Zealanders Bill Submission
Recently, MSNZ made a submission to the Accessibility for New Zealanders Bill. The intention of the proposed bill is to establish “a new legislative framework that addresses systemic accessibility barriers that prevent disabled people, tāngata whaikaha and their whānau, and others with accessibility needs from living independently and participating in all areas of life”. Following […]
Making progress to make Autologous Hematopoietic Stem Cell Treatment (aHSCT) an available treatment option in NZ for MS
Autologous Hematopoietic Stem Cell Treatment (aHSCT) is an intense chemotherapy treatment which aims to wipe out harmful immune cells and rebuild the immune system. aHSCT is a life-improving treatment halting the disease and disability in its tracks. A person receiving aHSCT will potentially need NO further treatment. Following treatment, many PwMS report improvements to mobility, […]